KCT0005056尚未招募未知
A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy with Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 490
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1)Patients with histologically confirmed adenocarcinoma of biliary tract canacer (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer) after curative intent R0 or R1 surgical resection
- •2)Pathologic disease stage of T2-4, N0-2, M0 after surgery, according to AJCC 8th TNM staging
- •3)Patients who complete resection (R0 or R1 resection) for biliary tract cancer within 12 weeks of the adjuvant chemotherapy
- •4)No distant metastasis
- •5)ECOG performance sstatus score of 0 or 1
- •6)Age 19 years or older
- •7)Adequate bone marrow fuction (neutrophils = 1.5 x 109/L, platelets = 100 x 109/L and hemoglobin =9 g/dL)
- •8)Adequate liver function (total bilirubin < 1.5 fold the upper limit of normal of the study site (ULN), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 x ULN)
- •9)Adequate kidney function (Creatinine < 1.5 x ULN)
- •10) Unresolved systemic active infection (except for chronic viral hepatitis taking antiviral drugs)
- •11)Not receiving other drugs for clinical trials or chemotherapy within 30 days prior to randomization
- •12)A female participant who is not post-menopausal or amenorrhea less than 12 consecutive months without specific reasons is eligible to participate if she is not pregnant, confirmed by serum tests within 7 days before the initiation of chemotherapy
- •13)The participants provide written informed consent for the study.
- •14)No prior chemotherapy for biliary tract cancer
- •15)Participants of childbearing potential must agree to use an adequate method of contraception for the course of the study throught 120 days after the last dose of chemotherapy (oral contraceptives or mechanical contraception such as intrauterine devices or contraceptive barriers and etc). Childbearing potential female is who is not post-menopausal or amenorrhea less than 12 consecutive months without specific reasons.
排除标准
- •1)Other histology type than adenocarcinoma (such as HCC-CCC mixed type or neuroendocrine tumor)
- •2)Ampula of vater cancer
- •3)Has known additional malignancy (participants with non-melanoma skin cancer, or carcinoma in situ (e.g. breast carcinoma, prostate cancer) that have undergone potentially curative therapy without recurrence for more than 3 years are not excluded)
- •4)Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject’s participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- •5)Has an active infection requiring systemic therapy (bacteria, virus, fungal, etc)
- •6)Has a known history of Human Immunodeficiency Virus (HIV)
- •7)Has an active of hepatitis A or B (patients under anti-B-viral treatment with HBV DNA 1000=copies/ml is allowed to particiapte).
- •8)Has a history of severe hemorrhage (gastrointestinal or neurologic) within 2 weeks prior randomization
- •9)Is unable to take oral drug due to gastrointestinal obstruction or any other conditions.
- •10)Any history of significant cardiac disease within 3 months prior to randomization including unstable angina, NYHA (The New York Heart Association )III or IV congestive heart failure, myocardiac infarction, or severe uncontrolled arrhythmias
- •11)Pregnant, breast-feeding or pregnancy test positive female patients
- •12)Has any contraindications for investigational drug
- •-History of hypersensitivity to capecitabine or gemcitabine
- •-Any hypersensitivity to fluorouracil drugs
- •-Concurrent administration with sorivudine or brivudine
- •-DPD(dihydro-pyridine dehydrogenase) deficiency
- •-History of TS-1(tegafur / gimeracil / oteracil) administration
- •-Galactose intolerance, Lapp lactase deficince, glucose-galactose malabsorption
- •-Interstitial pneumonia or pulmonary fibrosis
研究者
相似试验
已完成
不适用
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab BETHPER-064-08F. HOFFMANN-LA ROCHE LTD.,34
进行中（未招募）
不适用
Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus BevacizumabEUCTR2007-005182-35-BGF. Hoffmann-La Roche Ltd.3,500
进行中（未招募）
不适用
Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab ve chemotherapy plus trastuzumab plus bevacizumabEUCTR2007-005182-35-IEF. Hoffmann-La Roche Ltd.3,500
进行中（未招募）
1 期
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - BETH (CIRG 011 (TRIO)/NSABP B-44-I)Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.MedDRA version: 9.1Level: HLGTClassification code 10006291Term: Breast neoplasms malignant and unspecified (incl nipple)EUCTR2007-005182-35-BEF. Hoffmann-La Roche Ltd.3,500
进行中（未招募）
不适用
A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab - BETH (CIRG 011 (TRIO)/NSABP B-44-I)Resected node-positive or high risk node-negative, invasive HER2-positive breast cancer.MedDRA version: 9.1Level: HLGTClassification code 10006291Term: Breast neoplasms malignant and unspecified (incl nipple)EUCTR2007-005182-35-LVF. Hoffmann-La Roche Ltd.3,500